Study identifier:D1960C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2009-009940-22
CTIS identifier:N/A
A Phase I, Single-Centre, Randomised, Double-Blind, Placebo Controlled Single-Ascending Dose, Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD8529 in Healthy Male Japanese Subjects
Healthy
Phase 1
Yes
AZD8529, Placebo
Male
48
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Aug 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This is a Phase I, double-blind, placebo-controlled, randomised within each dose group, single ascending dose study, with the objective to assess the safety, tolerability and pharmacokinetic profile of AZD8529 in healthy Japanese subjects.
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD8529 Oral |
Placebo Comparator: 2 | Drug: Placebo Oral |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.